Alternative Data for NRx Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 96 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 7 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,949 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 61 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 13,199 | Sign up | Sign up | Sign up |
| X Followers | 2,561 | Sign up | Sign up | Sign up |
| X Mentions | 12 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 14 | Sign up | Sign up | Sign up |
About NRx Pharmaceuticals
A clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain.
| Price | $1.86 |
| Target Price | Sign up |
| Volume | 743,662 |
| Market Cap | $59M |
| Year Range | $1.68 - $3.67 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSDMarch 9 - GlobeNewswire |
|
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation OfficerMarch 2 - GlobeNewswire |
|
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record DateJanuary 16 - GlobeNewswire |
|
 |
NRx Pharmaceuticals announces patient data on RWE on ketamine submitted to FDAJanuary 14 - Thefly.com |
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 ApprovalJanuary 14 - GlobeNewswire |
|
|
NRx Pharmaceuticals, neurocare partner for neuroplastic care offeringJanuary 5 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 240,000 | 97,000 | 150,000 | -5.9M | -5.8M | -0.507 |
| Q2 '25 | 0 | 0 | 0 | -18M | -18M | -0.980 |
| Q1 '25 | 4,000 | 2,000 | 2,000 | -5.5M | -5.5M | -0.340 |
| Q4 '24 | 4,000 | 1,000 | -1,000 | -9.1M | -9.1M | -0.770 |
| Q3 '24 | 0 | 2,000 | -2,000 | -1.6M | -1.6M | -0.150 |
Insider Transactions View All
| Javitt Jonathan C filed to buy 84,634 shares at $1.2. December 18 '24 |
| Hurvitz Chaim filed to buy 570,000 shares at $0.3. September 11 '23 |
| Gorovitz Aaron filed to buy 105,000 shares at $0.3. September 11 '23 |
| Javitt Jonathan C filed to buy 446,332 shares at $0.3. August 24 '23 |
| Javitt Jonathan C filed to buy 346,332 shares at $0.3. August 23 '23 |
Similar companies
Read more about NRx Pharmaceuticals (NRXP) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - NRx Pharmaceuticals
The Market Cap of NRx Pharmaceuticals is $59M.
Currently, the price of one share of NRx Pharmaceuticals stock is $1.86.
The NRXP stock price chart above provides a comprehensive visual representation of NRx Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling NRx Pharmaceuticals shares. Our platform offers an up-to-date NRXP stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, NRx Pharmaceuticals (NRXP) does not offer dividends to its shareholders. Investors interested in NRx Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of NRx Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
